| 0000-00-00 |
|
|
|
External link to document |
| 2021-07-27 |
126 |
Opinion - Memorandum Opinion |
one of the five patents-in-suit,
U.S. Patent No. 10,307,419 (the '" 419 patent"). The parties…; It is a bedrock principle of
patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321
(internal quotation marks omitted). The patent "specification…;Plaintiffs") allege infringement of five patents
against 18 pharmaceutical manufacturers seeking… Plaintiffs'
REXULTI® tablets before the patents expire. (D.I. 71 ; D.I. 92 at 1) 1 REXULTI® is |
External link to document |
| 2020-05-19 |
15 |
Redacted Document |
asserted U.S. Patent Nos. 9,265,831;
9,572,796; 9,572,797; and 10,010,533.
Case…agree that Claim 1 of U.S. Patent No. 9,572,796
(“the ’796 patent”), shown below in relevant…from the patent disclosures is that a
skilled artisan would understand the patents to disclose…on the Pleadings of Noninfringement of the '419 Patent by Biophore India Pharmaceuticals Private Ltd.,… Slayback Pharma LLC for infringing four patents covering
Eagle’s brand name bendamustine |
External link to document |
| 2019-10-11 |
4 |
Patent/Trademark Report to Commissioner of Patents |
,349,840; 8,618,109; 9,839,637; 10,307,419. (nmg) (Entered: 10/15/2019)
11 October 2019
PACER … Otsuka Pharmaceutical Co., Ltd.
5 10,307,419 06/04/2019 … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,888,362; 8,349,840… or G Patents.
✔ ( G the patent action involves… PRIVATE LTD.
PATENT OR DATE OF PATENT
|
External link to document |
| 2021-12-15 |
417 |
Redacted Document |
denying a motion for leave).
1
U.S. Patent Nos. 7,888,362; 8,349,840; 8,618,109; 9,839,637; and RE48,059…certification only as to the ’419 patent and not any of the other patents covering Otsuka’s
Rexulti® product…Paragraph IV certifications for the patents in suit, including the
’419 patent, to Paragraph III certifications…SUMMARY JUDGMENT OF NONINFRINGEMENT OF THE ’419 PATENT
{01752452;v1 }
Case 1:19-cv-01938-LPS Document…expiration
date of the other Orange Book listed patents.1 Specifically, Apotex provided notice of a Paragraph |
External link to document |
